Most patients with generalized Myasthenia Gravis need treatments that carry substantial risk of side effects and toxicity, Descartes-08 is a cell therapy is a RNA based CAR-T that causes direct killing of target cells without serious generalized toxicities.

The aim of this study is to measure the efficacy (how well it works) and safety of efgartigimod compared with placebo (inactive substance) in participants with ocular myasthenia gravis (oMG). The study will also measure the long-term efficacy, safety, and tolerability of efgartigimod.

Efgartigimod has been approved by the U.S. FDA (Food and Drug Administration) as a treatment for adult patients with gMG in whom AChR-Ab's are present. However, it was not approved it for the form of gMG that is AChR Ab seronegative (antibodies not present). and therefore this study is now testing how efragtigimod works in patients without any antibodies,